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Take Home Message
MRI ventilation defect post-bronchodilator reversibility was not always concordant with FEV1
reversibility in asthma and COPD. MRI VDP may provide enhanced sensitivity to small airway
response to inhaled medication.

To the Editor
The underlying pathophysiological determinants of asthma and chronic obstructive pulmonary
disease (COPD) are related in complex ways. Importantly however, post-bronchodilator FEV1 reversibility may occur in approximately 50% of COPD patients [1] whilst epidemiological [2]
and magnetic-resonance-imaging (MRI) studies [3] suggest that in asthmatics, FEV1 -reversibility
may diminish over time. As compared to patients with asthma or COPD alone, patients with coexisting asthma and COPD report worse clinical outcomes [4] and increased healthcare costs [5]
and burden [4, 5].

Hyperpolarised 3He and 129 Xe MRI studies have reported clinically relevant post-bronchodilator
improvements in MRI ventilation defects in patients with asthma [6] and COPD [7], independent
of FEV1 reversibility. However, post-bronchodilator FEV1 and MRI reversibility have not been
rigorously explored together across a wide range of patients with obstructive lung disease.
Although their etiology has not been ascertained, MRI ventilation defects are thought to be
related to airway occlusion or remodeling throughout the airway tree while FEV1 is dominated
by the larger airways.

To better understand bronchodilator reversibility in patients with a diagnosis of asthma or
COPD, we retrospectively evaluated spirometry and hyperpolarised 3He MRI measurements in
participants with asthma (age≥40-years, <1 pack-year smoking-history) and COPD (age 60-85years, >10 pack-years smoking-history).

We expected that MRI would detect post-

bronchodilator reversibility in participants in whom there was negligible post-bronchodilator
FEV1 -reversibility, thereby providing a small and large-airway quantitative functional

measurement with enhanced sensitivity to small airways disease and greater dynamic range than
FEV1.

We retrospectively evaluated 58 participants including 45 participants with asthma (20 male/25
female never-smokers, 54±8-years) and 13 with COPD (7 male/6 female ex-smokers, 70±6years, 45±17-pack-years) who underwent a single two-hour visit consisting of spirometry and
MRI before and after inhalation of salbutamol (4x100µg Teva Novopharm Ltd., Toronto,
Canada) using a pressurised metred-dose inhaler and AeroChamberPlus spacer (Trudell Medical
International, London, Canada). Spirometry was performed (MedGraphics, St. Paul, USA) and
post-bronchodilator reversibility assessed according to guidelines [8]. Participants withheld
short-acting β-agonists for 6-hours and long-acting β-agonists for 12-hours before their visit.
Anatomical proton and hyperpolarised 3He ventilation MRI were acquired after inhalation from
functional residual capacity as previously described [9].

We used the minimal clinically-

important-difference (MCID) of 110mL/2% [9] as the threshold for a clinically relevant postbronchodilator change in MRI ventilation-defect-percent (VDP) [9].

In asthma, 51% (23/45) of participants were FEV1 -reversible, whereas 15% (2/13) of COPD
participants were FEV1 -reversible.

Shown in Figure 1 (bottom panel), COPD and asthma

participants were further classified into eight subgroups based on FEV1 and VDP postbronchodilator reversibility where cyan represents both FEV1 and VDP reversibility, purple
represents either FEV1 or VDP reversibility and rose reflects neither FEV1, nor VDP
reversibility. Twenty-seven percent (12/45) of asthmatics and 15% (2/13) of COPD participants
exhibited both FEV1 and VDP reversibility (cyan).

As shown in rose, in 33% (15/45) of

participants with asthma and 62% of participants with COPD (8/13, ~double the proportion of
asthmatics) there was neither FEV1 nor VDP-reversibility. Shown in purple, 24% (11/45) of
asthmatics and no COPD participants demonstrated FEV1 reversibility in the absence of VDP
reversibility whilst 16% (7/45) of asthmatics and 23% (3/13) of COPD participants demonstrated
VDP reversibility in the absence of FEV 1 reversibility. Overall, VDP was greater in participants
with COPD compared with asthma (pre-bronchodilator 24±9% vs 10±8%, p<0.0001), although a
similar proportion of participants with COPD and asthma exhibited VDP reversibility (5/13 or
38% COPD; 19/45 or 42% asthma). Figure 1 also shows participant demographics and pre- and
post-bronchodilator hyperpolarised 3He static ventilation MRI, for representative participants
with both FEV1 and VDP reversibility, and with VDP reversibility alone. There was visually and
quantitatively improved ventilation post-bronchodilator even in participants who did not report
FEV1 improvements.

We observed a mixture of concordant and discordant FEV1 and MRI VDP reversibility in
asthmatic and COPD participants and were not surprised that nearly double the proportion of
participants with asthma reported concordant FEV1 and VDP reversibility (27% versus 15% in
COPD). We were surprised that nearly the same proportion of asthmatics reported neither FEV1
nor VDP reversibility (33%) which was about half the proportion of COPD (62%) reporting the
same. FEV1 reversibility in asthma may diminish over time, independent of smoking [2], and
therefore asthmatics may develop fixed obstruction in a mechanistically different way as
compared to COPD patients with post-bronchodilator reversibility [10, 11]. VDP was previously
shown to be an independent predictor of future bronchodilator reversibility in asthmatics [3] and
may help identify asthma patients at risk for fixed obstruction over time.

We also observed post-bronchodilator FEV1 and MRI ventilation improvements in a small
number of COPD patients, consistent with previous findings [7]. It is important to note that the
COPD participants studied here had no previous history of asthma, and may not meet current
asthma-COPD overlap definitions [10, 11]. VDP is temporally persistent and reproducible in
COPD [12], so it is possible that corresponding FEV1 and MRI VDP post-bronchodilator
improvements identify new phenotypes. Future studies in COPD patients with modest FEV1 and
VDP reversibility may show that these patients share similarities with asthma and might benefit
from asthma-targeted therapies.

Perhaps most enlightening was the observation in seven asthmatics and three COPD participants
who reported reversible VDP in the absence of FEV1 reversibility. This finding lends credence
to the growing understanding that FEV1 and VDP are measuring different but complementary
pathologies. Given that VDP is more sensitive to small airways disease than FEV1 and VDP
predicts future bronchodilator reversibility [3], the lack of VDP reversibility demonstrated in
16% of the asthma participants studied here may be an early indicator of progression to fixed
obstruction [2], that may stem from suboptimal treatment, inflammation, mucus plugging or
terminal airway obliteration. We note that two of these seven participants exhibited a postbronchodilator FEV1 improvement >+200 mL but did not meet the 12% threshold (230mL/9%,
260mL/11%) to satisfy ATS/ERS criteria [8].

The remainder reported post-bronchodilator

changes in FEV1 of -70mL/-4%, 160mL/6%, -50mL/-5%, 130mL/6% and 140mL/10%; some of
these post-bronchodilator changes are within the measurement error of FEV 1 [8]. Whilst 11
asthmatics reported FEV1 reversibility with no VDP reversibility, all FEV1 -reversible COPD

participants also reported VDP-reversibility. Different VDP and FEV1 responses in COPD and
asthma may be due to differences in large central airway obstruction and small airways disease
that is not detected using spirometry. Previous work showed that MRI in combination with
oscillometry revealed that VDP was related to total respiratory system and small airways
resistance before bronchodilator inhalation in asthma but was related only to small airways
resistance post-bronchodilator in asthma and COPD [13].

This supports the notion that

bronchodilator acts on the large airways in asthma, which could explain why so many
participants with asthma but none with COPD showed FEV1 reversibility with no VDP response.
These findings challenge us to reflect on the pathophysiological processes related to the distal or
peripheral airways which appear to dominate in COPD, but not asthma.

Our current understanding is that there are different asthma and COPD phenotypes with
distinctive pathophysiologies, including different contributions of the small and large airways
[1]. It was not unexpected that FEV1 and VDP reversibility were not always in agreement,
especially because VDP reflects both the small and large airways [14] and FEV1 measurements
are dominated by the large airways [15]. Importantly, VDP was not reversible in the majority of
participants (34/58 total). This is important to consider in small airways-disease-predominant
phenotypes, in whom reversibility may not be detected using spirometry, and this may be
considered for inhaled therapy response in general for patients with asthma and COPD. If
inhaled mediations are unable to reach the small airways, this could explain why only a subset of
patients experience improvements in symptoms or exacerbation frequency. VDP may provide a
new way to quantify small and large-airway function with enhanced sensitivity to small airways
disease and greater dynamic range than FEV1. Our results suggest the possibility for MRI VDP

to provide added value for assessing response to inhaled treatments, and perhaps demonstrate
different responses for inhalers specifically targeted at the small airways. VDP responses likely
depend on patient phenotype and the type of inhaled medication, and this opens the door for
future investigations to predict which patients will exhibit a VDP response to which inhaled
medication, in an effort to deliver personalised treatment.

We acknowledge that post-bronchodilator response remains controversial in patients with asthma
and COPD [11], and this limits the generalisability of our findings. Whilst age and smokinghistory were clearly different between groups, other parameters considered as key asthma and
COPD features [10, 11] including airway inflammation, age of disease-onset and/or disease
duration will be important to consider in future studies.

Post-bronchodilator MRI ventilation defect and FEV1 responses are not always concordant in
participants with asthma and COPD, suggesting that VDP may provide a more sensitive tool to
measure response to treatment in the small airways and identify the need for a change in
treatment.
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Figure 1. FEV1 and MRI VDP Reversibility in Participants with Asthma and COPD.
Centre slice hyperpolarised 3He MRI static ventilation (cyan) co-registered to
anatomical proton (gray-scale) pre- and post-bronchodilator for representative
participants with both FEV1 and MRI ventilation defect percent (VDP) reversibility, and
with VDP reversibility alone. Tables show demographics for asthma and COPD
participants. Cubic illustration shows eight subgroups with proportions of participants in
each based on FEV1 and MRI VDP reversibility, where cyan represents both FEV1 and
VDP reversibility, purple represents either FEV1 or VDP reversibility, and rose
represents neither FEV1 nor VDP reversibility.

